PCL Inc is a Korea-based company principally engaged in development and manufacture of vitro diagnostic medical device for immunological diagnosis. The Companyâ€™s products include blood bank screening products and quick diagnostic products. And the Company also provides platform services.

Employees

Sector

Biotechnology & Medical Research

More about the company

End-of-day quote Korea S.E. 2025-03-21			5-day change	1st Jan Change
6,040.00 ^KRW	-1.63%		-.--%	-

24-12-29	Yeom Ju-hwan agreed to acquire 36.90% stake in mCureX Therapeutics, Inc. from PCL, Inc. for KRW 13.0 billion.	CI
24-08-29	PCL, Inc. announced that it has received KRW 4.004999835 billion in funding	CI

Market Cap	16.8B 12.32M 11.05M 10.1M 9.22M 17.37M 1.16B 17.92M 122M 48.55M 618M 46.25M 45.26M 1.95B	P/E 2023	-7.17x	P/E 2024	-0.59x
Enterprise Value	23.83B 17.48M 15.68M 14.33M 13.08M 24.64M 1.64B 25.42M 173M 68.86M 877M 65.6M 64.2M 2.77B	EV / Sales 2023	22.8x	EV / Sales 2024	31.9x
Free-Float	98.99%	Yield 2023 *	-	Yield 2024	-

24-12-29	Yeom Ju-hwan agreed to acquire 36.90% stake in mCureX Therapeutics, Inc. from PCL, Inc. for KRW 13.0 billion.	CI
24-08-29	PCL, Inc. announced that it has received KRW 4.004999835 billion in funding	CI
24-08-21	PCL, Inc. announced that it expects to receive KRW 4.004999835 billion in funding	CI
24-06-24	PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from JS & Partners Co., Ltd.	CI
24-06-20	Tiger Company Ltd. announced that it has received KRW 8.3 billion in funding from PCL, Inc.	CI
24-01-15	PCL, Inc. announced that it has received KRW 9.99999885 billion in funding from Global Emerging Markets	CI
23-12-25	PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from Global Emerging Markets	CI
23-12-20	PCL, Inc. announced that it expects to receive KRW 9.99999885 billion in funding from Global Emerging Markets	CI
23-12-14	PCL, Inc. announced that it expects to receive KRW 9.99999838 billion in funding from JS & Partners Co., Ltd.	CI
23-05-31	South Korean Stocks Close Lower as Uncertainties Around US Debt Ceiling Deal Remain; PCL Loses 13%	MT
23-05-31	PCL to Raise 36 Billion Won via Share Issuance	MT
23-03-22	PCL, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
22-12-28	PCL, Inc. announced that it has received KRW 2.999990812 billion in funding from Hyeopsim Co ., Ltd.	CI

3 years	5,900	87,700
5 years	5,900	340,000
10 years	5,900	523,333.33

PCL, Inc. Stock

Stocks

A241820

KR7241820000

Biotechnology & Medical Research

Valuation: PCL, Inc.

Latest news: PCL, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: PCL, Inc.

Bio Diagnostics & Testing

Financials

Company Profile

Manager	Title	Age	Since
So-Yeon Kim CEO	Chief Executive Officer	55	-
Seong-Woo Lee SAM	Sales & Marketing	42	2024-03-27
Mu-Yong So AUD	Comptroller/Controller/Auditor	53	2024-03-27

Director	Title	Age	Since
So-Yeon Kim BRD	Director/Board Member	55	-
Chul-Joon Kim BRD	Director/Board Member	74	-
Mu-Yong So BRD	Director/Board Member	53	2024-03-27

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PCL, INC.	-1.63%	-.--%	-.--%	-89.21%	12.32M
WUXI APPTEC CO., LTD.	-4.83%	+3.51%	+55.00%	+62.02%	66.7B
ARGENX SE	+4.05%	+8.19%	+13.82%	+84.19%	56.88B
LONZA GROUP AG	+1.16%	+3.49%	+25.62%	+97.76%	56.53B
BEONE MEDICINES AG	+5.09%	+9.89%	+27.19%	+103.27%	46.49B
IQVIA HOLDINGS INC.	+2.62%	+1.68%	+29.16%	+36.08%	44.8B
REVOLUTION MEDICINES, INC.	+8.24%	+0.51%	+215.16%	+807.84%	41.59B
CELLTRION, INC.	-1.86%	+10.13%	+28.14%	+53.61%	35.35B
GENMAB A/S	+3.71%	-1.51%	+94.19%	+65.92%	33.29B
INSMED INCORPORATED	+5.19%	+1.62%	-39.69%	+381.71%	25.1B
Average	+2.17%	+2.03%	+44.86%	+160.32%	40.67B
Weighted average by Cap.	+2.11%	+3.07%	+50.54%	+167.52%

	2023	2024
Net sales	8.43B 6.18M 5.54M 5.07M 4.63M 8.71M 581M 8.99M 61.07M 24.35M 310M 23.2M 22.7M 979M	1.25B 914K 820K 749K 684K 1.29M 85.9M 1.33M 9.03M 3.6M 45.84M 3.43M 3.36M 145M
Net income	-20.32B -14.9M -13.36M -12.21M -11.15M -21M -1.4B -21.67M -147M -58.7M -747M -55.93M -54.73M -2.36B	-52.34B -38.38M -34.42M -31.46M -28.72M -54.11M -3.61B -55.81M -379M -151M -1.93B -144M -141M -6.08B
Net Debt	7.2B 5.28M 4.74M 4.33M 3.95M 7.45M 497M 7.68M 52.2M 20.81M 265M 19.83M 19.4M 837M	7.03B 5.16M 4.62M 4.23M 3.86M 7.27M 485M 7.5M 50.94M 20.31M 259M 19.35M 18.94M 816M